Literature DB >> 429572

Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon.

K Doi, M Prentki, C Yip, W A Muller, B Jeanrenaud, M Vranic.   

Abstract

Because in the dog, the gastric fundus contains the largest amount of glucagon immunoreactivity (IRG), the IRG of mucosal scrapes of 105 canine stomachs was extracted by acid-ethanol and then precipitated by ether-ethanol. The IRG recovered was measured by antisera 30K, specific for glucagon and K-4023, which cross-reacts with glucagon-like immunoreactivity. Extracts of mucosa of stomach fundus were further purified by gel filtration on Bio-Gel P-30 in 3M acetic acid. One pooled fraction corresponding to marker pancreatic glucagon in its elution volume was then gel-filtered on Bio-Gel P-30 in 0.05 M NH(4)HCO(3) and yielded one IRG peak, which, however, showed three immunoreactive components on polyacrylamide disc gel electrophoresis in urea. In addition, antiserum K-4023 reacted more strongly with that peak than antiserum 30K indicating the presence of glucagon-like immunoreactivity in this fraction. Subsequent ion-exchange column chromatography on DEAE-Sephadex A-25 and then CM-Bio-Gel A allowed purification to a single protein band on disc gel electrophoresis reacting equally to both antisera 30K and K-4023. 1.5 mug of purified gastric glucagon was obtained and its biological effects were compared to those of pancreatic glucagon in isolated rat hepatocytes. When immuno-equivalent amounts (300-2,500 pg/ml) of either type of glucagon were used, the same biological responses with respect to glycogenolysis and gluconeogenesis as well as urea, lactate, and pyruvate production were observed. Liver cyclic AMP was also raised to the same extent by either one of these hormones. We conclude that this moiety of gastric IRG is apparently identical to pancreatic glucagon because (a) their molecular weights, elution properties in ion exchange chromatography, and their electrophoretic mobility are indistinguishable and (b) both hormones elicited identical biological effects in isolated rat hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429572      PMCID: PMC371982          DOI: 10.1172/JCI109331

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  DEVELOPMENT OF PHOSPHORYLASE AND PHOSPHORYLASE-ACTIVATING (GLUCAGON-LIKE) SUBSTANCES IN THE RAT EMBRYO.

Authors:  G OKUNO; S PRICE; T A GRILLO; P P FOA
Journal:  Gen Comp Endocrinol       Date:  1964-08       Impact factor: 2.822

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  Extractable glucagon of the human pancreas.

Authors:  A J KENNY
Journal:  J Clin Endocrinol Metab       Date:  1955-09       Impact factor: 5.958

4.  Extrapancreatic glucagon in the dog.

Authors:  M Vranic; R Engerman; K Doi; S Morita; C C Yip
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

5.  Factors controlling gastric-glucagon release.

Authors:  P J Lefèbvre; A S Luyckx
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

6.  Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

Authors:  W A Muller; L Girardier; J Seydoux; M Berger; A E Renold; M Vranic
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

7.  Properties of immunoreactive glucagon fractions of canine stomach and pancreas.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  J Biol Chem       Date:  1977-03-25       Impact factor: 5.157

8.  Endocrine cells in oxyntic mucosa of a dog 5 years after pancreatectomy.

Authors:  M Ravazzola; D Baetens; R Engerman; N Kovacevic; M Vranic; L Orci
Journal:  Horm Metab Res       Date:  1977-11       Impact factor: 2.936

9.  Gastric A-cell function in insulin-deprived depancreatized dogs.

Authors:  E Blazquez; L Muñoz-Barragan; G S Patton; L Orci; R E Dobbs; R H Unger
Journal:  Endocrinology       Date:  1976-11       Impact factor: 4.736

10.  Measurement and partial characterization of immunoreactive glucagon in gastrointestinal tissues of dogs.

Authors:  S Morita; K Doi; C C Yip; M Vranic
Journal:  Diabetes       Date:  1976-11       Impact factor: 9.461

View more
  7 in total

Review 1.  Total pancreatectomy: indications, operative technique, and postoperative sequelae.

Authors:  David G Heidt; Charles Burant; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

2.  Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats.

Authors:  C L Brand; B Rolin; P N Jørgensen; I Svendsen; J S Kristensen; J J Holst
Journal:  Diabetologia       Date:  1994-10       Impact factor: 10.122

3.  Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis.

Authors:  S Del Prato; F Riva; A Devidé; R Nosadini; D Fedele; A Tiengo
Journal:  Acta Diabetol Lat       Date:  1980 Apr-Jun

4.  Regulation of glucose turnover during exercise in pancreatectomized, totally insulin-deficient dogs. Effects of beta-adrenergic blockade.

Authors:  O Bjorkman; P Miles; D Wasserman; L Lickley; M Vranic
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

5.  Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs.

Authors:  A Giacca; S J Fisher; Z Q Shi; R Gupta; H L Lickley; M Vranic
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Glucagon and carbohydrate disorder in a totally pancreatectomized man (a study with the aid of an artificial endocrine pancreas).

Authors:  F Santeusanio; M Massi-Benedetti; G Angeletti; G Calabrese; A Bueti; P Brunetti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

7.  Glucagon secretion and signaling in the development of diabetes.

Authors:  Herbert Y Gaisano; Patrick E Macdonald; Mladen Vranic
Journal:  Front Physiol       Date:  2012-09-04       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.